ROBERT BYRAM: Open Payments
NPI 1356528616 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,478 in 41 payments from 19 companies in 2025. Trend: 2023 $4,523 · 2024 $1,757 · 2025 $1,478
Food & beverage: $1,478
| Company | Payments | Amount |
|---|---|---|
| SOBI, INC | 4 | $297 |
| GENZYME CORPORATION | 3 | $292 |
| Incyte Corporation | 3 | $143 |
| Novo Nordisk Inc | 2 | $137 |
| Novartis Pharmaceuticals Corporation | 5 | $103 |
| Celgene Corporation | 5 | $97 |
| CSL Behring | 1 | $75 |
| Alexion Pharmaceuticals, Inc. | 3 | $58 |
| Janssen Biotech, Inc. | 3 | $56 |
| Astellas Pharma US Inc | 3 | $50 |
Products named: QFITLIA, Vonjo, NIKTIMVO, Alhemo, Fabhalta, REBLOZYL, HEMGENIX, ULTOMIRIS.
Industry payments across LA — which companies pay providers there.
